Principles of evidence-based management using stage I-II melanoma as a model

International Journal of Dermatology

Volumn 41, Issue 11, 2002, Pages 721-728

  Chuang, Tsu Yi ^a,b   Brashear, Ryan ^a,b   Wagner, Jeffrey D ^a,b   Farmer, Evan R ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b Richard L Roudeboush Vet Aff M   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN; INTERFERON; METHOTREXATE; PRIMECROLIMUS; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACCESS TO INFORMATION; ATOPIC DERMATITIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE MANAGEMENT; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; INTERNET; MEDICAL INFORMATION; MEDICAL LITERATURE; MELANOMA; META ANALYSIS; METASTASIS; NAIL INFECTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

DATABASES, BIBLIOGRAPHIC; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION STORAGE AND RETRIEVAL; MELANOMA; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0036858856     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2002.01504.x     Document Type: Review

References (41)

1. Sackett DL, Strauss SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and Teach EBM, 2nd edn. Edinburgh, Churchchill Livingstone; 2000.
2. Carruthers SG, Larochelle P, Haynes RB, et al. Report of the Canadian Hypertension Society Consensus Conference: I. Introduction. CMAJ, 1993; 149: 289-293.
3. Chuang T-Y, Reizner GT. Dermatoepidemiology. I. Epidemiological methods. Int J Dermatol, 1993; 32: 251-256.
4. Chuang T-Y, Faust HB, Farmer ER. Dermatoepidemiology. II. Causal inference established by a rule called "ASSOCIATED". Int J Dermatol, 1997; 36: 412-415.
5. Chuang T-Y, Mirowski G, Reizner GT. Dermatoepidemiology. Part III. ABC principles for critical review of the literature. Int J Dermatol, 1998; 37: 1-6.
6. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patents with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer, 2000; 89: 1495-1501.
7. Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 vs. 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8-2.0 mm: Randomized study by the Swedish Melanoma Study Group. Cancer, 1996; 77: 1809-1814.
8. Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: Long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol, 1996; 3: 446-452.
9. Balch CM, Urist MM. Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1-4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg, 1993; 218: 262-267.
10. Heenan PJ, English DR, Holman CD, Armstrong BK. The effects of surgical treatment on survival and local recurrence of cutaneous malignant melanoma. Cancer, 1992; 69: 421-426.
11. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol, 1998; 14: 272-275.
12. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med, 1988; 318: 1159-1162.
13. Veronesi U, Cascinelli N. Narrow excision (11-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg, 1991; 126(4): 438-441.
14. Hudson DA, Krige JEJ, Grobbelaar AO, et al. Melanorna of the face: The safety of narrow excision margins. Scand J Plast Reconstr Hand Surg, 1998; 32: 97-104.
15. Bono A, Bartoli C, Clemente C, et al. Ambulatory narrow excision for thin melanoma (< 2 mm): Results of a prospective study. Eur J Cancer, 1997; 33: 1330-1332.
16. O'Rourke MG, Altmann CR. Melanoma recurrence after excision. Is a wide margin justified? Ann Surg, 1993; 21: 2-5.
17. Marghoob AA, Koenig K, Bittencourt FV, et al. Breslow thickness and Clark level in melanoma. Cancer, 2000; 88: 589-595.
18. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7(2): 87-97.
19. Massi D, Franchi A, Borgononi L, et al. Thin cutaneous melanomas (< 15 mm). Identification of risk factors indicative of progression. Cancer, 1999; 85: 1067-1076.
20. Levi F, Randimbison IL, La Vecchia C, et al. Prognostic factors for cutaneous melanoma in Vaud, Switzerland. Int J Cancer, 1998; 78: 315-319.
21. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer, 1994; 73: 2324-2332.
22. Corona R, Mele SA, Ferrand G, et al. Survival and prognostic factors in patients with localized cutaneous melanoma observed between 1980 and 1991 at the Instituto Dermopatco deil'immacolata in Rome, Italy. Eur J Cancer, 1994; 30A: 333-338.
23. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma. Corroboration of a prognostic model. Cancer, 1997; 80: 1426-1431.
24. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 1996; 78: 427-432.
25. Clemente CG, Mihm MC, Butalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 1996; 77: 1303-1310.
26. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med, 1996; 125: 369-375.
27. Thorn M, Bergstrom R, Hedblad M, et al. Predictors of late mortality in cutaneous malignant melanoma - A population-based study in Sweden. Int J Cancer, 1996; 67: 38-44.
28. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer, 2000; 88: 1484-1491.
29. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanorna follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol, 1999; 140: 249-254.
30. Baughn CA, Hall W, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous melanorna: An audit. Clin Oncol, 1993; 5: 174-180.
31. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: A proposal for a follow-up schedule. Tumori, 1994; 80: 188-197.
32. Mooney MM, Kulas M, McKinley B, et al. Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol, 1998; 5: 54-63.
33. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology, 1995; 191: 199-203.
34. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patent or physician based? Ann Surg, 1995; 221: 566-571.
35. Terhune MH, Swanson NA, Johnson TM Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol, 1998; 134: 569-572.
36. Kagan R, Witt T, Bines S, et al. Gallium-67 scanning for malignant melanoma. Cancer, 1988; 61: 272-274.
37. Rinne D, Baurn RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patents. Cancer, 1998; 82: 1664-1671.
38. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patents undergoing sentinel node biopsy. J Clin Oncol, 1999; 17: 1508-1515.
39. Wagner JD, Gordon MS, Chuang T-Y, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer, 2000; 89: 453-462.
40. Wagner JD, Carbide IL, Park HM, et al. Sentinel lymph node biopsy for melanorna: Experience with 234 consecutive procedures. Plast Reconstr Surg, 2000; 105: 1956-1966.
41. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol, 2001; 45: 579-586.